98%
921
2 minutes
20
Connective tissue disease (CTD) is a collection of disorders characterized by various signs and symptoms such as circulation of autoantibodies in the entire system causing damage to internal organs. Interstitial lung disease (ILD) which is associated with CTD is referred to as CTD-ILD. Patients diagnosed with ILD should be thoroughly examined for the co-occurrence of CTD, since the treatment procedures and prognosis of CTD-ILD are vary from those of idiopathic interstitial pneumonia. The representative types of CTD which may accompany ILD include rheumatoid arthritis, systemic sclerosis (SSc), Sjögren's syndrome, mixed CTD, idiopathic inflammatory myopathies, and systemic lupus erythematous. Of these, ILD most frequently co-exists with SSc. If an ILD is observed in the chest, high resolution computed tomography and specific diagnostic criteria for any type of CTD are met, then a diagnosis of CTD-ILD is made. It is challenging to conduct a properly designed randomized study on CTD-ILD, due to low incidence. Therefore, CTD-ILD treatment approach is yet to been established in absence of randomized controlled clinical trials, with the exception of SSc-ILD. When a patient is presented with acute CTD-ILD or if symptoms occur due to progression of the disease, steroid and immunosuppressive therapy are generally considered.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778739 | PMC |
http://dx.doi.org/10.4046/trd.2019.0009 | DOI Listing |
Jpn J Clin Oncol
September 2025
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Background: Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study aimed to explore the appropriate initial dose of amrubicin for elderly patients with refractory, relapsed SCLC.
View Article and Find Full Text PDFJ Thorac Oncol
September 2025
Department of Radiology, Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. Electronic address:
Introduction: Interval lung cancers (ILCs) are key indicators of lung cancer screening (LCS) performance. However, data on the proportion, characteristics, and mortality of ILCs under biennial screening in Asian populations remain limited.
Methods: We analyzed participants from the baseline biennial Korean national LCS program between 2019 and 2020.
STAR Protoc
September 2025
Macrophage Lab, Department of Microbiology and Immunology, and Institute of Endemic Disease, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea; Cancer Researc
Interstitial macrophages increase significantly during lung metastasis and may contribute to tumor dissemination. However, isolating them is challenging due to their localization within lung tissue and phenotypic overlap with other immune cells. Here, we present a protocol for isolating and characterizing murine interstitial macrophages.
View Article and Find Full Text PDFZ Rheumatol
September 2025
Clinic of Internal Medicine III, Department of Oncology, Hematology, Cell and Immunotherapies, Clinical Immunology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Background: Interstitial lung diseases (ILD) represent an interdisciplinary clinical challenge and are not uncommonly associated with rheumatological diseases. Interstitial lung disease multidisciplinary meetings (ILD-MDM) provide a structured platform for interdisciplinary case discussions and decision making. Despite their great importance in patient care, data on the prevalence, structure and function of ILD-MDM in Germany are lacking.
View Article and Find Full Text PDFAnn Rheum Dis
September 2025
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Rheumatology, Oslo University Hospital, Oslo, Norway. Electronic address:
Background: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care.
Methods: A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies.